The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Risk factors for, and the pharmacokinetics of cisplatin induced renal Download Scientific Diagram Renal damage associated with heavy metals: review work Molecular signaling pathways in doxorubicin induced nephrotoxicity and potential therapeutic agents ScienceDirect